Blastic plasmacytoid dendritic cell neoplasm

Section editor
	Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO mwschoen

1 regimens on this page 1 variants on this page

All lines of therapy

Tagraxofusp monotherapy

back to top

Regimen

Study	Evidence
Frankel et al. 2014	Phase I/II, <20 pts

Chemotherapy

• Tagraxofusp (Elzonris) 12 mcg/kg IV over 15 minutes once per day on days 1 to 5

21-day cycles

References

1. Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article PubMed